SpringWorks Therapeutics Inc
NASDAQ:SWTX

Watchlist Manager
SpringWorks Therapeutics Inc Logo
SpringWorks Therapeutics Inc
NASDAQ:SWTX
Watchlist
Price: 34.63 USD -2.7% Market Closed
Market Cap: 2.6B USD

SpringWorks Therapeutics Inc
Investor Relations

SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development.

Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.

Show more
Loading

Earnings Calls

2024 Q3
Nov 12, 2024
Show Transcript
Previous
Next
SpringWorks Therapeutics Reports Strong Growth and Upcoming Launch Opportunities
2024 Q3
Nov 12, 2024

In its third quarter, SpringWorks Therapeutics celebrated a 23% quarter-over-quarter increase in OGSIVEO revenue, totaling $49.3 million, contributing to year-to-date earnings of $110.5 million. The firm remains confident in achieving profitability by mid-2026 and is expanding its market presence for OGSIVEO and mirdametinib. With an anticipated marketing approval for mirdametinib in February 2025, aimed at addressing a significant unmet need in NF1-PN patients, and ongoing positive patient outcomes with OGSIVEO, SpringWorks is poised for continued growth, driven by a robust clinical and commercial strategy.

Show Full Analysis

Management

Mr. Saqib Islam J.D.
CEO & Director
No Bio Available
Mr. Francis I. Perier Jr., M.B.A.
Chief Financial Officer
No Bio Available
Dr. Badreddin Edris Ph.D.
Chief Operating Officer
No Bio Available
Dr. James Cassidy M.D., Ph.D.
Chief Medical Officer
No Bio Available
Mr. Michael P. Nofi
Chief Accounting Officer
No Bio Available
Mr. Tai-An Lin Ph.D.
Chief Scientific Officer
No Bio Available
Ms. Kim Diamond
Vice President of Communications & Investor Relations
No Bio Available
Mr. Herschel S. Weinstein J.D.
General Counsel & Secretary
No Bio Available
Mr. Daniel J. Pichl
Chief People Officer
No Bio Available
Mr. Bhavesh Ashar M.B.A.
Chief Commercial Officer
No Bio Available

Contacts

Address
CONNECTICUT
Stamford
100 Washington Blvd
Contacts